Choose Excellence, Choose Concept to Market LLC

Your Gateway To Success In The Evolving Pharmaceutical Landscape

Concept to Market LLC is a consultancy firm focused on small molecules, biologics and medical devices across the development continuum with expertise in business development, non-dilutive and dilutive funding, product development and project, contract and financial management.

Our highly qualified team has on average over 25 years of experience which we employ to service pharmaceutical & biotech organizations of all types and sizes, including virtual companies, start-ups, small biotechs, clinical-stage biotechs, established biopharmaceutical companies, non-profit research organizations, academic institutions & technology transfer organizations, and healthcare investors.

Our comprehensive consulting services are flexible, customizable based on your needs, and designed to help with strategic & tactical support in seamless collaboration with client project teams. We are committed to helping our clients succeed.

Barbara Solow, PH.D.

Dr. Solow has over 25 years of experience in leading complex programs in pharmaceutical and biotechnology development for the U.S. Government including development and supply contracts with values exceeding $1 billion. She has managed over 150 personnel across three research and development sites with as many as six development projects at different stages of development running in parallel. Projects have ranged from discovery through post-licensure supply contracts for biologics, small molecules and devices. Customers have included the NIH, Biomedical Advanced Research and Development Authority (BARDA), Department of Defense and Department of State. Therapeutic areas have included infectious diseases, cancer and drug addiction.

Robert Hopkins, MD, MPH and TM

Dr. Hopkins is a board-certified internist and infectious disease specialist with over 25 years of experience in regulatory affairs, product development, project management, clinical development and clinical operations. His passion is to develop and license medical products that address significant medical needs. He served as a Medical Officer and Team Leader at the Center for Drug Evaluation Research (CDER), FDA in the Divisions of Special Pathogens and Immunologic Drug Products and Anti-Infective Drug Products and subsequently held clinical/product development positions at Merck, DynPort Vaccine Company, Emergent Biosolutions, and Aeras prior to serving as CMO at Adaptive Phage Therapeutics (APT) and Ocugen. He also served as a Senior Medical Advisor to the Biomedical Advanced Research and Development Authority (BARDA) and has developed multiple products that currently exist in the US Strategic National Stockpile (SNS).

Patrick D. Saam

Mr. Saam has over 25 years of experience in finance and accounting, with extensive experience in biotech manufacturing, government accounting, forecasting and planning, process development, contracting, and continuous improvement. Proven ability to manage diverse resources and exceed financial goals through increased efficiencies, process reengineering, team building and strategic networking